The Spectrum of FIP1L1-PDGFRA-Associated Chronic Eosinophilic Leukemia

@article{Legrand2013TheSO,
  title={The Spectrum of FIP1L1-PDGFRA-Associated Chronic Eosinophilic Leukemia},
  author={F. Legrand and Aline Renneville and E. Macintyre and Samuel Mastrilli and F. Ackermann and J. Cayuela and P. Rousselot and A. Schmidt-Tanguy and O. Fain and M. Michel and J. D. de Jaur{\'e}guiberry and P. Hatron and P. Cony-Makhoul and D. Lefranc and D. Sène and V. Cottin and M. Hamidou and O. Lidove and A. Baruchel and S. Dubucquoi and O. Bl{\'e}try and C. Preudhomme and M. Capron and L. Prin and J. Kahn},
  journal={Medicine},
  year={2013},
  volume={92},
  pages={e1 - e9}
}
AbstractImatinib is the treatment of choice for FIP1L1/PDGFRA (F/P)-associated chronic eosinophilic leukemia (F/P+ CEL), but its optimal dosing, duration, and possibility of discontinuation are still a matter of debate. A retrospective multicenter study was conducted with 44 F/P+ CEL patients identified in the French Eosinophil Network and treated with imatinib. The most frequently involved systems were skin (57%), spleen (52%), and lung (45%), and eosinophilic heart disease was observed in 15… Expand
Imatinib discontinuation for hypereosinophilic syndrome harboring the FIP1L1-PDGFRA transcript
TLDR
A subset of patients with hypereosinophilic syndrome (HES) may harbor an interstitial deletion in chromosome 4, leading to the creation of the FIP1L1-PDGFRA (F/P) fusion gene which has been found to be highly imatinibsensitive, which has shown that IM can be discontinued safely in at least some CML patients. Expand
Treatment-free remission in FIP1L1-PDGFRA-positive myeloid/lymphoid neoplasms with eosinophilia after imatinib discontinuation.
TLDR
The data demonstrate that imatinib can be safely stopped in FIP1L1-PDGFRA-positive MLN-eo because of a high treatment-free remission at 12 and 24 months and because most patients achieve a rapid second CMR after restart ofImatinib. Expand
Imatinib for the treatment of hypereosinophilic syndromes
  • G. Helbig
  • Medicine
  • Expert review of clinical immunology
  • 2018
TLDR
Imatinib mesylate, a first generation tyrosine kinase inhibitor, has revolutionized the therapeutic approach to patients with hypereosinophilic syndromes and detectable F/P fusion gene. Expand
Pediatric hypereosinophilia: FIP1L1-PDGFRA myeloproliferative disease in a 14-year-old male
TLDR
The exquisite sensitivity of the FIP1L1-PDGFRA fusion to the tyrosine kinase inhibitor Imatinib, abrogates the short-term life threatening complications of hyper-eosinophilia. Expand
The Lymphoid Variant of Hypereosinophilic Syndrome
TLDR
Clinical manifestations related to CD3-CD4+ T cell-associated L-HES are not limited to skin, and can involve all tissue or organs affected in other types of HE, and CS are always effective in these patients, but CS-sparing treatments are frequently needed. Expand
Jak postępujemy u chorego z zespołem hipereozynofilowym
TLDR
This review presents the current state of knowledge on definitions, classifications and treatment of HES in the molecular era and indicates the PDGFRA/B-positive population has an excellent prognosis. Expand
Epidemiology, clinical picture and long‐term outcomes of FIP1L1‐PDGFRA‐positive myeloid neoplasm with eosinophilia: Data from 151 patients
TLDR
In F/P+ MN‐eo, prompt initiation of IM and longer treatment durations may prevent relapses after discontinuation of IM, which is highly efficient but no predictive factor of relapse after discontinisation has yet to be identified. Expand
Comment on: First report of FIP1L1-PDGFRα-positive eosinophilic granulomatosis with polyangiitis.
TLDR
It is concluded that, in patients with CAPS refractory to usual therapy, eculizumab may be an effective alternative, and its efficacy in cases such as the authors' supports its cost-effectiveness for this condition with high mortality and morbidity. Expand
Myeloid neoplasms with eosinophilia.
TLDR
Myeloid mutation panels have identified somatic variants in patients with a provisional diagnosis of hypereosinophilia of undetermined significance, reclassifying some of these cases as eos inophilia-associated neoplasms. Expand
Diagnosis and Novel Approaches to the Treatment of Hypereosinophilic Syndromes
TLDR
Several new biologics and tyrosine kinase inhibitors have been shown to lower eosinophil numbers, but more randomized trials are needed to confirm efficacy in HES. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 34 REFERENCES
Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders.
TLDR
Although the drug was well tolerated in most patients, a previously unrecognized treatment toxicity of acute left ventricular dysfunction occurred in a responding patient with HES within the first week of treatment. Expand
FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia.
TLDR
FIP1L1-PDGFRA is a relatively infrequent but treatment-relevant mutation in primary eosinophilia that is indicative of an underlying systemic mastocytosis. Expand
Relapse following discontinuation of imatinib mesylate therapy for FIP1L1/PDGFRA-positive chronic eosinophilic leukemia: implications for optimal dosing.
TLDR
The data are consistent with suppression rather than elimination of the clonal population in FIP1L1/PDGFRA-positive CEL and suggest that molecular monitoring may be the most useful method in determining optimal dosing without the risk of disease exacerbation. Expand
Clinical and molecular features of FIP1L1-PDFGRA (+) chronic eosinophilic leukemias
TLDR
FIP1L1-PDGFRA (+) CEL emerges as a homogeneous clinicobiological entity, where imatinib can induce molecular remission, and while RT-PCR and interphase FISH are equally valid diagnostic tools, the role of marrow biopsy in diagnosis and of RQ- PCR in disease and therapy monitoring needs further evaluation. Expand
Clinical characteristics of patients with chronic eosinophilic leukaemia (CEL) harbouring FIP1L1‐PDGFRA fusion transcript—results of Polish multicentre study
TLDR
Significant clinical symptoms are infrequent present and splenomegaly remains the most common organ involvement in patients with CEL expressing F/P fusion transcript, and the long‐term remission on imatinib in this patient population is confirmed. Expand
Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy.
TLDR
This study, the largest clinical analysis of patients with HES to date, provides useful information for clinicians but also should stimulate prospective trials to optimize treatment of HES. Expand
Cell clonality in hypereosinophilic syndrome: what pathogenetic role?
TLDR
It is suggested that a real distinction between m- and l-HES is not wholly convincing and that clonal T-cell expansion could not be the "primum movens" but an epiphenomenon in HES. Expand
The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRα-positive hypereosinophilic syndrome. Results of a multicenter prospective study
TLDR
All patients meeting the criteria for idiopathic or primary HES should be screened for the FIP1L1-PDGFRα rearrangement, and chronic imatinib treatment at doses as low as 100 mg daily ensures complete and durable responses. Expand
Myeloid neoplasm with prominent eosinophilia and PDGFRA rearrangement treated with imatinib mesylate
TLDR
Treatment with imatinib resulted in complete and durable clinical, hematological, and molecular remission within 3 months after starting treatment, and a 2‐year‐old female with a myeloid neoplasm associated with eosinophilia and rearrangement of PDGFRA was reported. Expand
KIT D816V-associated systemic mastocytosis with eosinophilia and FIP1L1/PDGFRA-associated chronic eosinophilic leukemia are distinct entities.
TLDR
The hypothesis that the FIP1L1/PDGFRA gene fusion and D816V-KIT mutation cause distinct clinical syndromes is reinforced. Expand
...
1
2
3
4
...